ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARP Annual Meeting 2019

Abstract Number: 1683

Cardiac Involvement of Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss): Initial Manifestations and Outcomes Based on Data from a Monocenter Patient Cohort

Silvia Sartorelli 1, Pascal Cohen 2, Bertrand Dunogue 2, Alexis Régent 2, Xavier Puéchal for the French Vasculitis Study Group 2, Luc Mouthon 2, Loic Guillevin 2 and Benjamin Terrier2, 1Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Milan, Italy, 2National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARP Annual Meeting 2019

Keywords: Churg-Strauss syndrome, Myocardial involvement, outcomes and systemic vasculitides

Session Information

Date: Monday, November 11, 2019

Title: Vasculitis – ANCA-Associated Poster II

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic necrotizing vasculitis characterized by blood and tissue eosinophilia, and asthma. Its cardiac involvement is a major concern that was previously described as the most important predictor of death; however, definitions of that involvement differ according to study. We aimed to describe the first EGPA cardiac manifestations and outcomes in recent decades.

Methods: This retrospective, monocenter study included all EGPA patients followed in our vasculitis center. Patients’ and disease characteristics were recorded at diagnosis and throughout follow-up, especially cardiac assessments. Cardiac involvement was defined as clinical or extra-clinical signs of patent cardiopathy, with no other potential causes identified.EGPA relapses, major cardiac-related events (i.e. acute and chronic heart failure, atrial fibrillation and/or ventricular tachycardia, ischemic cardiopathy) and causes of death were recorded.

Results: The 150 EGPA patients (78 men; mean±SD age 47.8±15.9 years) included were characterized by asthma (99%), eosinophilia (95%), sinonasal abnormalities (84%), pulmonary infiltrates (51%), peripheral neuropathy (57%) and eosinophil-rich infiltrates (19%); 39% were ANCA+. Median baseline BVAS was 17.5 [IQR 13–22].

Sixty-five (43%) patients had cardiac involvement, 55 (85%) diagnosed at EGPA diagnosis and 10 (15%) during follow-up. The main clinical cardiac manifestations included chest pain (16%), peripheral edema (8%), palpitations (4%), cardiogenic shock (3%) and arrhythmia (1%). Patients with cardiac involvement, compared to those without, respectively, were less frequently ANCA+ (27% vs. 48%, P=0.02), had less frequent peripheral neuropathy (46% vs. 66%, P=0.02), and had higher eosinophil count (9748±7639 vs. 6346±5291/mm3, P=0.004).

Patients with cardiac involvement had abnormal ECG (70%), abnormal echocardiography [(68%; mainly pericardial effusion (42%) and left ventricular dysfunction (31%)] and cardiac MRI abnormalities [(98%; with left ventricular dysfunction (43%), myocardial edema (24%) and late gadolinium enhancement (74%)]. However, ECG, echocardiography and cardiac MRI, respectively, were also abnormal for 32%, 40% and 61% of the patients without patent cardiopathy.

After mean follow-up of 121±97.2 months, 65 (43%) patients experienced EGPA relapses, with no between-group differences (37 vs 48%, P=0.19). However, 46% of patients with cardiac involvement had cardiac relapses. Major heart-related events occurred in 17/150 (11%) patients, most often those with known cardiac involvement (18% vs. 6%, P=0.02). Finally, 4 patients died but none from cardiac causes.

Conclusion: Cardiac involvement is frequent in EGPA in a tertiary referral center, especially in patients without ANCA, with higher eosinophil counts and no peripheral neuropathy. Long-term outcome was better than previously reported. However, in the absence of a consensual definition of cardiac involvement, comparisons among studies remains difficult.


Disclosure: S. Sartorelli, None; P. Cohen, None; B. Dunogue, None; A. Régent, None; X. Puéchal for the French Vasculitis Study Group, LFB, 8, Pfizer, 2, 8, Roche, 8; L. Mouthon, None; L. Guillevin, None; B. Terrier, Grifols, 8, GSK, 8, LFB, 8, Roche, 8.

To cite this abstract in AMA style:

Sartorelli S, Cohen P, Dunogue B, Régent A, Puéchal for the French Vasculitis Study Group X, Mouthon L, Guillevin L, Terrier B. Cardiac Involvement of Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss): Initial Manifestations and Outcomes Based on Data from a Monocenter Patient Cohort [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/cardiac-involvement-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss-initial-manifestations-and-outcomes-based-on-data-from-a-monocenter-patient-cohort/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cardiac-involvement-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss-initial-manifestations-and-outcomes-based-on-data-from-a-monocenter-patient-cohort/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology